Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2019 | 1 |
2021 | 1 |
2022 | 1 |
2024 | 0 |
Search Results
3 results
Results by year
Filters applied: . Clear all
Page 1
Soluble programmed cell death-1 predicts hepatocellular carcinoma development during nucleoside analogue treatment.
Sci Rep. 2022 Jan 7;12(1):105. doi: 10.1038/s41598-021-03706-w.
Sci Rep. 2022.
PMID: 34996935
Free PMC article.
This study included 122 NA-naive patients who received NA therapy. We assessed the associations of clinical factors, including soluble immune checkpoint proteins, with HCC development during NA treatment. ...Of the 16 proteins, soluble inducible T-cell co-stimulator ( 164. …
This study included 122 NA-naive patients who received NA therapy. We assessed the associations of clinical factors, including solubl …
Deneddylation by SENP8 restricts hepatitis B virus propagation.
Chen DV, Suzuki T, Itoh Y, Maeda Y, Hirano J, Haga S, Zhang H, Ito D, Matsuura Y, Okamoto T.
Chen DV, et al.
Microbiol Immunol. 2021 Mar;65(3):125-135. doi: 10.1111/1348-0421.12874. Epub 2021 Feb 24.
Microbiol Immunol. 2021.
PMID: 33433029
Free article.
Item in Clipboard
Switching to tenofovir disoproxil fumarate vs continuing treatment in patients with chronic hepatitis B who maintain long-term virological response to entecavir therapy: A randomized trial.
Iida-Ueno A, Enomoto M, Kozuka R, Tamori A, Kawada N.
Iida-Ueno A, et al.
J Med Virol. 2019 Jul;91(7):1295-1300. doi: 10.1002/jmv.25442. Epub 2019 Mar 12.
J Med Virol. 2019.
PMID: 30815880
Clinical Trial.
Item in Clipboard
Cite
Cite